If these checks fail, route to clinical review or reject as incomplete because inconsistent clinical answers undermine criteria-based adjudication
For example, previous research has shown that females appear to be more sensitive to the ability of GLP-1R agonists to suppress food intake and body weight (e.g., Richard et al., 2016)
100% achieved 5% Weight loss was dose-dependent: 4mg (-17.1%), 8mg (-22.8%), 12mg (-24.2%) at 48 weeks Results appeared early (visible by week 4) and continued throughout the 48-week trial Beyond weight: significant improvements in blood pressure, lipids, liver fat, and glycemic control Investigational Drug: Retatrutide is not FDA-approved
Researchers studying the role of dual incretin signaling may prefer tirzepatide, which provides a direct way to study GLP-1/GIP interaction effects
Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use